One-week versus two-week combination amphotericin B and flucytosine for induction therapy of HIV-associated cryptococcal meningitis

Phase 3

• Conditions: induction treatment; antifungal; amphotericin B; Age more than 18 yearsHIV infectionDiagnosis of cryptococcal meningoencephalitis; cryptococcal meningoencephalitis; HIV; flucytosine

• Registration Number: TCTR20190719001
• Lead Sponsor: Faculty of Medicine Siriraj Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-07-19
• Study Completion: 2021-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Enrolling by invitation
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

1. HIV-infected patients, 18 years of age or older,
2. Admitted at Siriraj Hospital and another 11 hospitals
3. Definite diagnosis of cryptococcal meningitis

Exclusion Criteria

1. Allergic to amphotericin B or flucytosine
2. Receive amphotericin B or flucytosine more than 72 hours
3. Women who were pregnant or during breast feeding
4. Other fungal infection which treatment by amphotericin B

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality rate 4 weeks Number of population

Secondary Outcome Measures

Name	Time	Method
Fungal clearance 14 days Culture,Adverse effect of treatment 14 days Laboratory test,Recurrence rate 90 days Presentation of recurrent Infection